Researchers at the University of Cambridge have completed the first human trial of a DNA-based vaccine designed entirely by artificial intelligence. This experimental vaccine aims to provide universal protection against the entire sarbecovirus family, including the viruses responsible for COVID-19, SARS, and emerging animal variants, according to findings published in the Journal of Infection.
How AI creates variant-proof vaccines
Traditional vaccines rely on training the immune system to recognize one specific viral strain. However, as viruses mutate, these vaccines often lose efficacy, necessitating frequent updates. According to the University of Cambridge, the AI-designed vaccine bypasses this by analyzing genetic data from thousands of related viruses. The AI identifies stable, shared features—the parts of the virus that evolution has left largely untouched—and targets these as the basis for the vaccine. This approach seeks to provide immunity against an entire viral family rather than just a single strain.
Unlike the mRNA technology used for many COVID-19 vaccines, this new approach uses DNA. DNA vaccines are more stable, which simplifies storage and transport—a vital advantage for regions with limited “cold-chain” infrastructure.
Why universal protection matters for future pandemics
Broad-spectrum vaccines could fundamentally change how public health officials respond to emerging threats. By targeting stable features, such a vaccine could potentially stop new outbreaks before they evolve into global pandemics. This research is particularly relevant for rapidly evolving diseases like influenza, where the annual race to match vaccines to circulating strains often falls short. Furthermore, the current Ebola outbreak in the Democratic Republic of the Congo and Uganda, driven by the Bundibugyo strain, highlights the urgent need for vaccines that cover entire virus families, as existing options may not provide protection against every variant.
Results from the first human trial
The first human trial of this AI-designed vaccine confirmed that the technology is safe and well-tolerated, according to the Journal of Infection. Participants showed an immune response, with the vaccine successfully stimulating the production of antibodies that recognize different types of sarbecoviruses. While these initial results are encouraging, the study noted that immune responses were modest. Further research is required to determine the duration of protection and whether boosters will be necessary. Larger trials are the next step to verify if the vaccine can effectively reduce infection rates in real-world settings.
The vaccine’s delivery system is needle-free. It uses a high-pressure liquid stream to deliver the dose through the skin, which may reduce discomfort and increase the speed of mass vaccination efforts during an outbreak.
Frequently Asked Questions
- Is this vaccine available now? No. While the first human trial is complete, a universal vaccine remains a few years away from clinical use.
- How is this different from a standard COVID-19 shot? Standard vaccines target specific strains. This AI-designed vaccine targets stable genetic features shared across an entire family of viruses.
- Are DNA vaccines safe? The recent trial found the DNA-based technology to be safe and well-tolerated by human participants.
What are your thoughts on the role of AI in medical research? Share your views in the comments below or subscribe to our newsletter for the latest updates on medical technology and public health developments.
